...
首页> 外文期刊>Journal of Ocular Pharmacology and Therapeutics >Trans-scleral Delivery of Antiangiogenic Proteins
【24h】

Trans-scleral Delivery of Antiangiogenic Proteins

机译:跨巩膜递送抗血管生成蛋白

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein.nnMethods: At several time points after the injection, the retina, retinal pigmented epithelium/choroid, and sclera were dissected and enzyme-linked immunosorbent assays were performed.nnResults: After a periocular injection of AdsFlt-1.10, AdTGFβ.10, or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor-β (TGF-β) were not significantly different from scleral levels, and choroidal levels of sFlt-1 (soluble Flt-1 or soluble VEGF receptor 1) were only moderately reduced from scleral levels, indicating that each of these proteins penetrate the sclera well. In contrast, retinal levels of each of the three proteins were low compared to choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked 2 h after a periocular injection of PEDF protein and returned to baseline between 6 and 24 h, and peak levels in the retina were 8.6% of peak choroidal levels. Levels of green fluorescent protein, a protein unlikely to have any binding sites in mouse tissues, peaked in the choroid 2 h after the periocular injection and were undetectable by 4 h, while peak levels in the retina were 64.3% of peak choroidal levels.nnConclusions: These data suggest that size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50–75 kDa penetrate well into the choroid, but not into the retina. Periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but additional investigations are needed before they can be considered for treatment of retinal diseases.
机译:目的:在这项研究中,我们研究了眼周注射蛋白质或表达该蛋白质的腺病毒载体(Ad)后各种蛋白质对小鼠眼的渗透。nn方法:注射后几个时间点,视网膜,视网膜色素沉着结果:眼周注射AdsFlt-1.10,AdTGFβ.10或AdPEDF.11后,脉络膜色素上皮衍生因子(PEDF)的水平发生变化,并转化为上皮/脉络膜和巩膜并进行酶联免疫吸附测定。生长因子-β(TGF-β)与巩膜水平无显着差异,而sFlt-1(可溶性Flt-1或可溶性VEGF受体1)的脉络膜水平仅从巩膜水平适度降低,表明这些蛋白均渗透巩膜很好。相比之下,与脉络膜水平相比,这三种蛋白质各自的视网膜水平都较低,这表明渗透到视网膜的能力很差。眼周注射PEDF蛋白后2小时,脉络膜中PEDF的水平达到峰值,并在6至24 h之间恢复到基线,而视网膜中的峰值水平为脉络膜峰值的8.6%。绿色荧光蛋白的水平是一种在小鼠组织中不太可能具有任何结合位点的蛋白,在眼周注射后2 h在脉络膜中达到峰值,到4 h仍未检测到,而视网膜中的峰值水平是脉络膜峰值的64.3%.nn结论:这些数据表明,蛋白质的大小和结合特性可能会影响其从眼周间隙穿透眼睛的能力,但通常,大至50–75 kDa的蛋白质会很好地穿透脉络膜,但不会穿透视网膜。眼周注射可以用表达它们的蛋白质或载体来治疗脉络膜新生血管,但在考虑将其用于治疗视网膜疾病之前还需要进一步研究。

著录项

  • 来源
  • 作者单位

    Anna M. Demetriades Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD.Tye Deering Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD.Hansheng Liu Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD.Lili Lu Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD.Peter Gehlbach Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD.Jonathan D. Packer Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD.Feilim Mac Gabhann Department of Biomedical Engineering, The Johns Hopkins University, School of Medicine, Baltimore, MD.Aleksander S. Popel Department of Biomedical Engineering, The Johns Hopkins University, School of Medicine, Baltimore, MD.Lisa L. Wei GenVec, Inc., Gaithersburg, MD.Peter A. Campochiaro Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD.Department of Neuroscience, The Johns Hopkins University, School of Medicine, Baltimore, MD.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Trans-scleral, Antiangiogenic Proteins, PEDF;

    机译:跨巩膜;抗血管生成蛋白;PDF;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号